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rundowns are the only functional changes occurring in HH tissue.
Gap junctions are cell-to-cell channel-forming structures formed by
specialized proteins (connexins [Cx]) which allow direct electrical cou-
pling and chemical communication between adjacent neurons in cen-
tral nervous system (CNS) (Cruikshank et al., 2005). Cx36 is the main
neuronal connexin, although others have been variably detected in ma-Hypothalamic hamartoma (HH) is a rare (about 1:100,000) develop-
mental, non-neoplastic malformation involving the small hypothalamic
area located between the infundibular stalk and themammillary bodies
(Maixner, 2006). HH can be associatedwith a range of neurological and/
or endocrinogical manifestations (Striano et al., 2005; Munari et al.,
1995). However, HH typical clinical hallmarks are compulsive bursts
of laughter of epileptic naturewith no sense ofmirth, called gelastic sei-
zures, and ﬁrst described by Trousseau in 1877 (Berkovic et al., 1998).
These attacks usually start during infancy or childhood and were dem-
onstrated to originate directly from the HH (Striano et al., 2009). More-
over, inmost patients, other seizure typesmay occur in associationwith
a severe encephalopathy that can eventually lead to intellectual disabil-
ity within few years (Berkovic et al., 1998; Striano et al., 2009). Antisei-
zure drugs are inexorably ineffective and cannot avoid the cognitive
dysfunction whereas the catastrophic evolution can be interrupted up
to completely reverted by HH surgical ablation (Striano et al., 2009).
Hence, this potentially reversible encephalopathy is an amazing in
vivo model to investigate the process of human epileptogenesis and to
ﬁnd new therapeutic options in patients with drug-resistant epilepsy.
The intrinsic epileptogenicity of HH is explained by the peculiar
anatomo-functional organization and, in particular, by the electrophys-
iological properties of small acid gamma-aminobutyric (GABA)-ergic
neurons that make this structure highly epileptogenic and refractory
to antiseizure drugs, regardless their mechanism of action. Li and col-
leagues (Li et al., 2011) previously demonstrated, by means of patch-
clamp recordings, the functional rundown of GABA-A receptors in
neurons from surgically resected HH tissue, in line with the view that
a dysfunction of GABAergic transmission plays a crucial role inom.2016.04.026.
y, G. Gaslini Institute, Italy.
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. This is an open access article underepileptogenesis in these patients. Nonetheless, it is unlikely that GABA
ture neurons. In most CNS regions, including the cortex and hypothala-
mus, the incidence of neuronal gap-junctions physiologically increases
during the ﬁrst two postnatal weeks and then decrease by the end of
the third–fourth week. Cx36 and gap-junctions expression are tran-
siently stimulated following a wide range of neuronal injuries, such as
ischemia, spinal cord injury, epilepsy and inﬂammation (Belousov &
Fontes, 2013).
Gap junctions likely contribute to the pathogenesis of epilepsy, par-
ticularlywith respect to enhancing synchronousGABA activity of neuro-
nal subgroupswithin epileptic networks (Cruikshank et al., 2005; Traub
et al., 2004). However, although the pharmacological blockade of gap
junctions signiﬁcantly reduces seizure occurrence (Traub et al., 2004),
the potential for gap-junction blockers for treatment of human epilepsy
remains still largely unexplored.
In this issue of EBioMedicine, Wu and colleagues demonstrated that,
in human HH, neuronal gap junctions between small GABAergic HH
neurons participate in the genesis of epileptic-like discharges (Wu et
al., 2016). The authors studied surgically resected HH tissue obtained
from27patients all affected by treatment-resistant epilepsy and a histo-
ry of gelastic seizures. Intellectual disability or developmental retarda-
tion was present in 13 (48%) patients and prior history of central
precocious puberty was present in nine (33%) subjects. Wu and col-
leagues showed that HH tissue displayed a marked up-regulation of
Cx43 and Cx36 protein levels when compared to normal hypothalamic
control tissue. The increase of both connexins may relate to immature
properties of HH tissue and immunohistochemistry conﬁrmed that
Cx36 was mainly expressed within neuron clusters while Cx43 was de-
tected outside of neuronal networks. Biocytin injection into single re-
corded small HH neurons showed labeling of adjacent neurons, which
was not observed in the presence of the neuronal gap-junction blocker,
meﬂoquine. Finally, microelectrode ﬁeld recordings from freshly
resected HH slices demonstrated spontaneous ictal/interictal-like dis-
charges which were signiﬁcantly reduced by the application of gap-
junction blockers without alterations of the action-potential ﬁring of
small GABA neurons observed with patch-clamp whole-cell recordings.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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mental approaches, these data clearly support amechanistic role of neu-
ronal gap junctions in the intrinsic epileptogenicity of human HH and
strenghten the cellularmodel inwhichHHneuron clusters of spontane-
ously ﬁring interneurons paradoxically excite projection neurons in a
functional network (Belousov & Fontes, 2013). Although the increase
in Cx36 may be due to the developmental phenotype of HH neurons,
the study suggests relevant insights on future therapeutic strategies,
i.e. the use of gap-junction blockers such as carbenoxolone and
tonabersat, to address the severely drug-refractory epileptic encepha-
lopathy that affects patients.
There are open questions as yet, however. It is still possible that nei-
ther neuronal gap junctions or impaired GABAergic function are the pri-
mary mechanisms that contribute to epileptogenesis in these patients,
and that they can represent a secondary or compensatory event.
Finally, much more importantly, the electrophysiological features of
HH neurons do not explain per se the natural history of HH patients, i.e.
the epileptic encephalopathy that occurs in most cases with deteriora-
tion in seizure type and development of neocortical onset of seizures
(secondary epileptogenesis), along with the progression of cognitive
impairment and psychiatric features (Berkovic et al., 1998; Striano et
al., 2009) with consequent reduction in autonomy.
Is there a contribution of neuronal gap-junctions to the propagation
of pro-damage molecules between the coupled neurons (Belousov &
Fontes, 2013)? Clariﬁcation of the transcriptional/biochemical events
that underlie Cx36-dependent neuronal developmental alterations
and analysis of their role in HH and in the entire epileptogenic network
are areas of great interest and hold potential translational value for the
development of novel therapeutic targets. In the meantime, increased
awareness of the syndrome, timely diagnosis, and appropriate treat-
ment are needed to minimize long-term cognitive impairment and be-
havioral disturbances and to avoid a catastrophic evolution for the
patients.Disclosures
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